Status:
UNKNOWN
Estradiol-mediated Neural Plasticity as Potential Mediator of Neurofeedback Treatment Change for Traumatized Women
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Posttraumatic Stress Disorder (PTSD)
Eligibility:
FEMALE
18-62 years
Phase:
NA
Brief Summary
Post-traumatic stress disorder (PTSD) is a common debilitating disorder that affects many individuals exposed to aversive events. The severity of PTSD symptoms is positively correlated with amygdala a...
Detailed Description
Pretreatment phase- All participants will undergo clinician evaluation, self-report measures and emotional regulation tasks in TASMC. In addition, participants will undergo a functional and structural...
Eligibility Criteria
Inclusion
- Women of age (18-62) :
- Treated at Clinic for Sexual Assault with stable symptoms.
- Fulfill screening criteria of DSM-V for PTSD. -
Exclusion
- Pregnancy.
- Fulfill screening criteria of DSM-V for psychosis.
- Substance dependence or abuse other than nicotine.
- Diagnosis of a neurodegenerative disease.
- Acute illness that could be worsen by the treatment. -
Key Trial Info
Start Date :
January 13 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 20 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03416764
Start Date
January 13 2019
End Date
February 20 2022
Last Update
February 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv Sourasky Medical Center Tel Aviv, Israel
Tel Aviv, Israel